Traders sold shares of United Therapeutics Corporation (NASDAQ:UTHR) on strength during trading on Friday following insider selling activity. $58.77 million flowed into the stock on the tick-up and $80.63 million flowed out of the stock on the tick-down, for a money net flow of $21.86 million out of the stock. Of all stocks tracked, United Therapeutics Corporation had the 21st highest net out-flow for the day. United Therapeutics Corporation traded up $9.85 for the day and closed at $136.81Specifically, CEO Martine A. Rothblatt sold 1,248 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $126.41, for a total value of $157,759.68. Following the sale, the chief executive officer now owns 2,317 shares of the company’s stock, valued at approximately $292,891.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Giltner sold 3,490 shares of the stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $131.12, for a total value of $457,608.80. The disclosure for this sale can be found here. Insiders sold a total of 23,758 shares of company stock worth $3,058,699 in the last ninety days. 7.80% of the stock is owned by corporate insiders.
UTHR has been the topic of a number of recent analyst reports. J P Morgan Chase & Co set a $125.00 price objective on United Therapeutics Corporation and gave the company a “hold” rating in a report on Tuesday, April 11th. Jefferies Group LLC reiterated a “sell” rating and issued a $116.00 price objective on shares of United Therapeutics Corporation in a report on Wednesday, April 12th. HC Wainwright reiterated a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a report on Monday, April 17th. Cowen and Company reiterated a “hold” rating and issued a $121.00 price objective on shares of United Therapeutics Corporation in a report on Wednesday, April 26th. Finally, Wedbush reiterated an “outperform” rating and issued a $213.00 price objective (down previously from $229.00) on shares of United Therapeutics Corporation in a report on Thursday, April 27th. Six investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $134.50.
The stock has a market cap of $5.94 billion, a PE ratio of 15.87 and a beta of 1.51. The stock has a 50-day moving average price of $130.70 and a 200-day moving average price of $136.25.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same quarter in the previous year, the company earned $4.42 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Analysts expect that United Therapeutics Corporation will post $14.47 earnings per share for the current fiscal year.
United Therapeutics Corporation announced that its Board of Directors has initiated a stock buyback plan on Thursday, April 27th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 4.6% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.
A number of hedge funds have recently made changes to their positions in UTHR. Focused Wealth Management Inc boosted its stake in shares of United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 140 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of United Therapeutics Corporation during the first quarter valued at about $147,000. Daiwa Securities Group Inc. boosted its stake in shares of United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of United Therapeutics Corporation during the first quarter valued at about $204,000. Finally, Eagle Global Advisors LLC purchased a new stake in shares of United Therapeutics Corporation during the second quarter valued at about $206,000.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).